-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Esophageal cancer is one of the common malignant tumors in China.
Esophageal cancer is one of the common malignant tumors in China.
The ESCORT-1 st study is a randomized, double-blind, placebo-controlled, phase III clinical study conducted in more than 60 centers across the country.
The ESCORT-1 st study is a randomized, double-blind, placebo-controlled, phase III clinical study conducted in more than 60 centers across the country.
The study finally included 596 patients, 298 cases in each of the Carrelizumab combined chemotherapy group and the chemotherapy group
Similarly, the Carrelizumab combined chemotherapy group significantly improved the patients’ median progression-free survival (PFS) compared with the chemotherapy group, which were 6.
The 6-month, 12-month, and 18-month survival rates of the combination group and single chemotherapy group were 89.
The ORR of the two groups were 72.
Treatment-related serious adverse events occurred in 296 patients (99.
Adverse events
In summary, the study showed that Carrelizumab combined with chemotherapy first-line treatment significantly improved the prognosis of patients with advanced esophageal squamous cell carcinoma
In summary, the study showed that Carrelizumab combined with chemotherapy first-line treatment significantly improved the prognosis of patients with advanced esophageal squamous cell carcinoma
Original source:
Luo H, Lu J, Bai Y, et al.
ESCORT-1st Investigators.
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial .
JAMA.
2021 Sep 14;326(10):916-925.
doi: 10.
1001/jama.
2021.
12836.
PMID: 34519801.
ESCORT-1st Investigators.
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial .
JAMA.
2021 Sep 14;326(10):916-925.
doi: 10.
1001/jama.
2021.
12836.
PMID: 34519801.
Leave a message here